Literature DB >> 22267126

Different signal intensity at Gd-EOB-DTPA compared with Gd-DTPA-enhanced MRI in hepatocellular carcinoma transgenic mouse model in delayed phase hepatobiliary imaging.

Huedayi Korkusuz1, Lea L Knau, Wolfgang Kromen, Verena Bihrer, Daniel Keese, Albrecht Piiper, Thomas J Vogl.   

Abstract

PURPOSE: To evaluate hyperintense Gd-DTPA- compared with hyper- and hypointense Gd-EOB-DTPA-enhanced magnet resonance imaging (MRI) in c-myc/TGFα transgenic mice for detecting hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Twenty HCC-bearing transgenic mice with overexpression of the protooncogene c-myc and transforming growth factor-alpha (TGF-α) were analyzed. MRI was performed using a 3-T MRI scanner and an MRI coil. The imaging protocol included Gd-DTPA- and Gd-EOB-DTPA-enhanced T1-weighted images. The statistically evaluated parameters are signal intensity (SI), signal intensity ratio (SIR), contrast-to-noise ratio (CNR), percentage enhancement (PE), and signal-to-noise ratio (SNR).
RESULTS: On Gd-DTPA-enhanced MRI compared with Gd-EOB-DTPA-enhanced MRI, the SI of liver was 265.02 to 573.02 and of HCC 350.84 to either hyperintense with 757.1 or hypointense with 372.55 enhancement. Evaluated parameters were SNR of HCC 50.1 to 56.5/111.5 and SNR of liver parenchyma 37.8 to 85.8, SIR 1.32 to 1.31/0.64, CNR 12.2 to 26.1/-30.08 and PE 42.08% to 80.5/-98.2%, (P < 0.05).
CONCLUSION: Gd-EOB-DTPA is superior to Gd-DTPA for detecting HCC in contrast agent-enhanced MRI in the c-myc/TGFα transgenic mouse model and there was no difference between the hyperintense or hypointense appearance of HCC. Either way, HCCs can easily be distinguished from liver parenchyma in mice.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22267126     DOI: 10.1002/jmri.23584

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  4 in total

1.  Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.

Authors:  Jörg Haupenthal; Verena Bihrer; Huedayi Korkusuz; Otto Kollmar; Christian Schmithals; Susanne Kriener; Knut Engels; Thomas Pleli; Alexander Benz; Marta Canamero; Thomas Longerich; Bernd Kronenberger; Swantje Richter; Oliver Waidmann; Thomas J Vogl; Stefan Zeuzem; Albrecht Piiper
Journal:  Neoplasia       Date:  2012-05       Impact factor: 5.715

Review 2.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

3.  Gd-EOB-DTPA-enhanced MRI for quantitative assessment of liver organ damage after partial hepatic ischaemia reperfusion injury: correlation with histology and serum biomarkers of liver cell injury.

Authors:  Tobias Getzin; Faikah Gueler; Björn Hartleben; Marcel Gutberlet; Anja Thorenz; Rongjun Chen; Martin Meier; Jan Hinrich Bräsen; Thorsten Derlin; Dagmar Hartung; Hannah A S Lang; Hermann Haller; Frank Wacker; Song Rong; Katja Hueper
Journal:  Eur Radiol       Date:  2018-04-30       Impact factor: 5.315

4.  Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T.

Authors:  Cecilia Besa; Suguru Kakite; Nancy Cooper; Marcelo Facciuto; Bachir Taouli
Journal:  Acta Radiol Open       Date:  2015-01-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.